Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnP + Serplulimab + SBRT for Locally Advanced Pancreatic Cancer
NCT07101679Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Started Apr 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07101679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101679.